Patient perspectives on treating psoriasis with classic inpatient dithranol therapy: a retrospective patient survey.

Abstract

BACKGROUND:

Evidence of the efficacy of dithranol and patient perspectives on the treatment is scant.

PATIENTS AND METHODS:

Using a telephone interview survey, we collected retrospective data from 63 patients (41 men [65.1 %] and 22 women [34.9 %]) who had been treated with classic inpatient dithranol (CID). PsoRA (www.psoriasisregistry.at) was used to obtain clinical data and treatment responses, which were then correlated with the interview responses.

RESULTS:

Fifty-two (82.5 %) patients achieved a PASI75 and 51 (81 %) a PASI90 response within a median of 12.5 (range: 3 to 25) days. Ten out of twelve (83 %) patients showed a satisfactory response to CID (PASI75 or greater reduction) despite the fact that they had previously failed to adequately respond to methotrexate, oral retinoids, cyclosporine, or ustekinumab. Overall, patients recalled a median recurrence-free interval of four (95 % CI: 3-9) months after responding to CID, which was positively correlated with the patients' recommendation of (p = 0.018) and their overall high satisfaction with the treatment (p = 0.012).

CONCLUSIONS:

Despite the known limitations of CID, this survey indicates that dithranol remains a highly efficacious and valuable treatment option as induction therapy in psoriasis. CID can be effective in patients who have failed to respond to systemic therapy, including traditional agents and biologics.

• Authors: Clemens Painsi, Michael Patscheider, Martin Inzinger, Bernhard Lange-Asschenfeldt, Franz Quehenberger, Peter Wolf
• Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (J Dtsch Dermatol Ges) Vol. 13 Issue 11 Pg. 1156-63 (Nov 2015) ISSN: 1610-0387 [Electronic] Germany
• PMID: 26513076 (Publication Type: Journal Article)
• Copyright: © 2015 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.

Chemical References

• Dermatologic Agents
• Anthralin

Topics

• Adolescent
• Adult
• Age Distribution
• Aged
• Anthralin (therapeutic use)
• Austria (epidemiology)
• Dermatologic Agents (therapeutic use)
• Female
• Health Care Surveys
• Hospitalization (statistics & numerical data)
• Humans
• Male
• Middle Aged
• Patient Participation (psychology, statistics & numerical data)
• Patient Satisfaction (statistics & numerical data)
• Prevalence
• Psoriasis (drug therapy, epidemiology, psychology)
• Quality of Life (psychology)
• Retrospective Studies
• Risk Factors
• Sex Distribution
• Young Adult